Glyburide Tablet shortage
To Be Discontinued 4 presentations · 1 manufacturers · first FDA posting 2026-08-10 · last update 2026-08-10
Manufacturers: Sanofi-Aventis U.S. LLC
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Diabeta, Tablet, 5 mg (NDC 0093-9364-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 08/10/2026 Updated 08/10/2026 Discontinued 08/10/2026 |
| Diabeta, Tablet, 5 mg (NDC 0093-9364-10) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 08/10/2026 Updated 08/10/2026 Discontinued 08/10/2026 |
| Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 08/10/2026 Updated 08/10/2026 Discontinued 08/10/2026 |
| Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 08/10/2026 Updated 08/10/2026 Discontinued 08/10/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)